Navigation Links
Omnicell Announces Second Quarter 2009 Results
Date:7/23/2009

mance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, earnings per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of SFAS No. 123R. We recognize equity plan-related compensation expenses, which represents the fair value of all share-based payments to employees, including grants of employee stock options, as required under SFAS No. 123 (revised 2004), "Share-Based Payment" (SFAS No.123R).

b) Restructuring charges (net of tax). We incurred
'/>"/>

SOURCE Omnicell, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Omnicell to Release Second Quarter 2009 Earnings Results on July 23
2. Omnicell Improves Nursing Workflow with New Anywhere RN(TM) Remote Medication Management Application
3. Omnicell Boosts Pharmacy Efficiency with Enhanced WorkflowRx(TM) Central Pharmacy Automation Software
4. Omnicell Announces First Quarter 2009 Results
5. Omnicell to Release First Quarter 2009 Earnings Results on April 30
6. Omnicell Unveils Tissue Center Solution - Industrys First Integrated Tissue Tracking and Compliance System
7. Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems
8. Omnicell is Awarded Contract by Major National Academic Medical Center
9. Omnicell is Awarded Sole-source Contract by Emory Healthcare
10. Omnicell to Release Fourth Quarter 2008 Earnings Results on January 29
11. Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Frozen shoulder (Adhesive capsulitis) affects ... to develop this nasty condition which occurs most frequently in ... last up to two and half years if not treated. ... and with good reason: it can render your shoulder so ... is, if you aren't in too much pain to get ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... a garden might help soothe the agitation that commonly strikes ... 17 past studies, British researchers found evidence that watering plants, ... some dementia patients, anxiety. The study authors cautioned that ... subject to study -- and the evidence of a benefit ...
(Date:7/30/2014)... breastfed for three months or more as babies ... associated with cardiovascular and metabolic diseases, according to ... in St. Louis. , "This study shows that ... health decades later," said Molly W. Metzger, PhD, ... co-author of the study with Thomas W. McDade, ...
(Date:7/30/2014)... Everyone knows that the internet is the absolute center ... looking for something to buy, trying to reconnect with friends, ... pretty much always going to be the go to resource. ... so happy to announce the launch of their brand new ... age. Whether a person wants to know what the Sierra ...
(Date:7/30/2014)... The North America aviation actuator market is ... America is expected to be the fastest growing region ... of 5.60%. , The commercial aircraft market offers ... assume prominence in the years to come. Commercial aviation ... has regained quickly, and the industry has been reliably ...
Breaking Medicine News(10 mins):Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4
... Wagoner on new data showing first increase in U.S.,teen ... that the,dramatic decrease in teen pregnancy rates in the ... a screeching halt. This unwelcome,development should not come as ... success over the last decade -- the decline in ...
... of,Hematology (ASH), the world,s largest professional society of ... notable,contributions to the genetic understanding of disease. Carlo ... intended to honor an individual,with a distinguished career ... receive the William Dameshek Prize, awarded to an ...
... HEI, Inc. (Nasdaq: HEII ),( http://www.heii.com ) ... with the,Securities and Exchange Commission to voluntarily deregister its ... expects that the,deregistration will be effective after 90 days, ... deregister. As a result of this filing, HEI,s,obligation to ...
... found in household fittings has been found to affect the ... will be required to determine if the presence of this ... the online open access journal BMC Genomics is the first ... profile. , Jose Russo and coworkers from the Fox Chase ...
... A new study in the Annals,of Emergency Medicine ("Increasing ... United States, 1993 to 2003") finds the rate of,elderly ... any,other group., Kenneth L. Noller, MD, President of ... statement about the,study on behalf of the Alliance of ...
... air pollution, especially diesel exhaust , , WEDNESDAY, Dec. 5 ... the health damage done by automotive air pollution, especially ... period of improving air quality in Switzerland, which started ... measurable benefits in lung function for adults as they ...
Cached Medicine News:Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 2Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 3Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 3Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... funding commitment from a prominent international research and ... focus on promoting innovative research-based initiatives, including those ... nasal spray for the delivery of naloxone that ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... announced today that the Company,s Chairman and CEO Byron ... taking place September 7-9.  BioBDx manufactures and markets the ... related to deficits in response inhibition. The ... measurement of hyperactivity, impulsivity and inattention as an aid ...
... NEW YORK, Aug. 31, 2011 The Prix Galien ... in biopharmaceutical research and development, announced today that Dr. ... Humanum Award during the 5th Annual Prix Galien USA ... of other awards honoring companies who have made innovative ...
Cached Medicine Technology:BioBDx to Present at the 2011 BioPharm America Conference 2Dr. Paul Farmer Selected as 2011 Pro Bono Humanum Honoree by Prix Galien USA 2
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... The Affinity pacemaker ... today's smallest, truly automatic ... effective combination of advanced ... Affinity DR pacemaker incorporates ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... The Guidant INSIGNIA Ultra ... patient-specific, easy-to-use features for ... enhanced patient safety. All ... programmed using the ZOOM ...
Medicine Products: